Bristol-Myers Squibb Sees Mixed Analyst Sentiment, Cramer Notes Buying Opportunities

Pharmaceutical giant Bristol-Myers Squibb (BMY) is experiencing mixed analyst sentiment, with Jim Cramer specifically highlighting recent stock pullbacks as excellent buying opportunities despite broader industry momentum.